范可尼贫血症通路影响肿瘤耐药、化疗增敏的研究进展  

Research progress on effects of Fanconi anemia pathway on tumor drug resistance and chemotherapy sensitization

作　　者：杨淑贤 余克富[1] 孙阿宁 史卫忠[1] 赵志刚[1] YANG Shuxian;YU Kefu;SUN Aning;SHI Weizhong;ZHAO Zhigang(Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China)

机构地区：[1]首都医科大学附属北京天坛医院药学部,北京100070

出　　处：《现代药物与临床》2024年第3期785-790,共6页Drugs & Clinic

基　　金：北京市医院管理局临床医学发展专项扬帆计划(ZYLX201827)。

摘　　要：范可尼贫血症是一种罕见的人类遗传疾病,常伴有癌症易感性、骨髓衰竭和发育异常。范可尼贫血症基因编码的蛋白和相关蛋白构成范可尼贫血症通路。该通路参与DNA损伤修复,与肿瘤发生、肿瘤耐药、化疗药物增敏等密切相关。归纳了范可尼贫血症通路组成及其参与DNA损伤修复过程,讨论了范可尼贫血症通路的调控、对肿瘤耐药、化疗敏感性的影响,并总结了靶向范可尼贫血症通路的小分子抑制剂,为癌症干预提供新思路。Fanconi anemia is a rare human genetic disease,often accompanied by susceptibility to cancer,bone marrow failure,and dysplasia.The proteins and related proteins encoded by the Fanconi anemia gene constitute the Fanconi anemia pathway.This pathway is involved in DNA damage repair and is closely related to tumor development,tumor resistance,and chemotherapy sensitization.This article summarizes the composition of the Fanconi anemia pathway and its involvement in DNA damage repair processes.It discusses the regulation of the Fanconi anemia pathway,and its impact on tumor drug resistance and chemotherapy sensitivity,and summarizes small molecule inhibitors targeting the Fanconi anemia pathway,which will provide new ideas for cancer intervention.

关 键 词：范可尼贫血症通路 DNA损伤修复 肿瘤耐药 化疗增敏 抑制剂 

分 类 号：R973[医药卫生—药品]